WCBA
BIVV

Weaver C. Barksdale & Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$6K Buy
113
+18
+19% +$985 0.01% 367
2017
Q3 		$5K Buy
95
+6
+7% +$351 0.01% 385
2017
Q2 		$5K Sell
89
-19
-18% -$1.08K 0.01% 392
2017
Q1 		$6K Buy
+108
New +$5.32K 0.01% 372

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Weaver C. Barksdale & Associates's BIVV Position: Q4 2017 in Review

Weaver C. Barksdale & Associates increased its Bioverativ Inc. Common Stock (BIVV) stake by 19% in Q4 2017, buying an estimated $985 and bringing the position to 113 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #367.

Weaver C. Barksdale & Associates first reported a position in BIVV in Q1 2017 and has held it in 4 quarters since. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Weaver C. Barksdale & Associates held 113 shares of Bioverativ Inc. Common Stock worth $6K as of Q4 2017.
  • Weaver C. Barksdale & Associates bought 18 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $985.
  • Bioverativ Inc. Common Stock made up 0.01% of Weaver C. Barksdale & Associates's portfolio in Q4 2017, its #367 holding.
  • Weaver C. Barksdale & Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and has held it in 4 quarters since.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.